Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting.

Purpose: Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient safety, as well as inform decisions related to treatment and continued trial participation. As prior research has demonstrated that conventional concordance metrics (e.g.